Publications

Publications 2024

  1. Fossum E, Rohringer A, Aune T, Rydland KM, Bragstad K, Hungnes O (2024)
    Antigenic drift and immunity gap explain reduction in protective responses against influenza A(H1N1)pdm09 and A(H3N2) viruses during the COVID-19 pandemic: a cross-sectional study of human sera collected in 2019, 2021, 2022, and 2023
    Virol J, 21 (1), 57
    DOI 10.1186/s12985-024-02326-w, PubMed 38448981
  2. Fossum E, Rohringer A, Aune T, Rydland KM, Bragstad K, Hungnes O (2024)
    Correction: antigenic drift and immunity gap explain reduction in protective responses against influenza A(H1N1)pdm09 and A(H3N2) viruses during the COVID-19 pandemic: a cross-sectional study of human sera collected in 2019, 2021, 2022, and 2023
    Virol J, 21 (1), 66
    DOI 10.1186/s12985-024-02341-x, PubMed 38500208
  3. Garcia I, Bråte J, Fossum E, Rohringer A, Moen LV, Hungnes O, Fjære O, Zaragkoulias K, Bragstad K (2024)
    Recombinant SARS-CoV-2 Delta/Omicron BA.5 emerging in an immunocompromised long-term infected COVID-19 patient
    Sci Rep, 14 (1), 25790
    DOI 10.1038/s41598-024-75241-3, PubMed 39468221
  4. Gopalakrishnan RP, Østrøm MS, Skjeldal FM, Bakke O, Bogen B, Huszthy PC (2024)
    B Cells With Complementary B Cell Receptors Can Kill Each Other
    Eur J Immunol, e202350890 (in press)
    DOI 10.1002/eji.202350890, PubMed 39520365
  5. Haghmorad D, Oksenych V, Huszthy PC (2024)
    Editorial: Exploring the role of T helper cells in autoimmune disease
    Front Immunol, 15, 1434684
    DOI 10.3389/fimmu.2024.1434684, PubMed 38903522
  6. Hinke DM, Anderson AM, Katta K, Laursen MF, Tesfaye DY, Werninghaus IC, Angeletti D, Grødeland G, Bogen B, Braathen R (2024)
    Applying valency-based immuno-selection to generate broadly cross-reactive antibodies against influenza hemagglutinins
    Nat Commun, 15 (1), 850
    DOI 10.1038/s41467-024-44889-w, PubMed 38346952
  7. Ng BD, Rajagopalan A, Kousa AI, Fischman JS, Chen S, Massa A, Elias HK, Manuele D, Galiano M, Lemarquis AL, Boardman AP, DeWolf S, Pierce J, Bogen B, James SE, van den Brink MRM (2024)
    IL-18-secreting multiantigen targeting CAR T cells eliminate antigen-low myeloma in an immunocompetent mouse model
    Blood, 144 (2), 171-186
    DOI 10.1182/blood.2023022293, PubMed 38579288
  8. Tunheim G, Fossum E, Robertson AH, Rø GØI, Chopra A, Vaage JT, Vikse EL, Kran AB, Magnus P, Trogstad L, Mjaaland S, Hungnes O, Lund-Johansen F (2024)
    Characterization of the SARS-CoV-2 antibody landscape in Norway in the late summer of 2022: high seroprevalence in all age groups with patterns of primary Omicron infection in children and hybrid immunity in adults
    BMC Infect Dis, 24 (1), 841
    DOI 10.1186/s12879-024-09670-w, PubMed 39164637

Publications 2023

  1. Baert L, Manfroi B, Quintero M, Chavarria O, Barbon PV, Clement E, Zeller A, Van Kuppevelt T, Sturm N, Moreaux J, Tveita A, Bogen B, McKee T, Huard B (2023)
    3-O sulfation of syndecan-1 mediated by the sulfotransferase HS3ST3a1 enhances myeloma aggressiveness
    Matrix Biol, 120, 60-75
    DOI 10.1016/j.matbio.2023.05.005, PubMed 37201729
  2. Benjakul S, Anthi AK, Kolderup A, Vaysburd M, Lode HE, Mallery D, Fossum E, Vikse EL, Albecka A, Ianevski A, Kainov D, Karlsen KF, Sakya SA, Nyquist-Andersen M, Gjølberg TT, Moe MC, Bjørås M, Sandlie I, James LC, Andersen JT (2023)
    A pan-SARS-CoV-2-specific soluble angiotensin-converting enzyme 2-albumin fusion engineered for enhanced plasma half-life and needle-free mucosal delivery
    PNAS Nexus, 2 (12), pgad403
    DOI 10.1093/pnasnexus/pgad403, PubMed 38077689
  3. Domenjo-Vila E, Casella V, Iwabuchi R, Fossum E, Pedragosa M, Castellví Q, Cebollada Rica P, Kaisho T, Terahara K, Bocharov G, Argilaguet J, Meyerhans A (2023)
    XCR1+ DCs are critical for T cell-mediated immunotherapy of chronic viral infections
    Cell Rep, 42 (2), 112123
    DOI 10.1016/j.celrep.2023.112123, PubMed 36795562
  4. Jadhav SS, Luboshits G, Bogen B, Firer MA (2023)
    Tracking the cellular immune response from early premalignancy to active multiple myeloma in a new model
    Eur J Immunol, 54 (1), e2350627
    DOI 10.1002/eji.202350627, PubMed 37872778
  5. Kikuchi J, Kodama N, Takeshita M, Ikeda S, Kobayashi T, Kuroda Y, Uchiyama M, Osada N, Bogen B, Yasui H, Takahashi N, Miwa A, Furukawa Y (2023)
    EMD originates from hyaluronan-induced homophilic interactions of CD44 variant-expressing MM cells under shear stress
    Blood Adv, 7 (4), 508-524
    DOI 10.1182/bloodadvances.2022007291, PubMed 35930695
  6. Métivier C, Le Saëc P, Gaschet J, Chauvet C, Marionneau-Lambot S, Hofgaard PO, Bogen B, Pineau J, Le Bris N, Tripier R, Alliot C, Haddad F, Chérel M, Chouin N, Faivre-Chauvet A, Rbah-Vidal L (2023)
    Preclinical Evaluation of a 64Cu-Based Theranostic Approach in a Murine Model of Multiple Myeloma
    Pharmaceutics, 15 (7)
    DOI 10.3390/pharmaceutics15071817, PubMed 37514004
  7. Tjärnhage E, Brown D, Bogen B, Andersen TK, Grødeland G (2023)
    Trimeric, APC-Targeted Subunit Vaccines Protect Mice against Seasonal and Pandemic Influenza
    J Virol, 97 (2), e0169422
    DOI 10.1128/jvi.01694-22, PubMed 36719241
  8. Vikse EL, Fossum E, Erdal MS, Hungnes O, Bragstad K (2023)
    Poor neutralizing antibody responses against SARS-CoV-2 Omicron BQ.1.1 and XBB in Norway in October 2022
    Influenza Other Respir Viruses, 17 (6), e13144
    DOI 10.1111/irv.13144, PubMed 37273461
  9. Werninghaus IC, Hinke DM, Fossum E, Bogen B, Braathen R (2023)
    Neuraminidase delivered as an APC-targeted DNA vaccine induces protective antibodies against influenza
    Mol Ther, 31 (7), 2188-2205
    DOI 10.1016/j.ymthe.2023.03.012, PubMed 36926694
  10. Westhrin M, Blazevski J, Textor A, Abdollahi P, Gopalakrishnan RP, Ngo LT, Hofgaard PO, Heinzelbecker J, Bobic S, Fossum E, Spång HCL, Braathen R, Bogen B (2023)
    Id-neoantigen vaccine induces therapeutic CD8+ T cells against multiple myeloma: H chain-loss escapees cause FLC MM
    J Immunother Cancer, 11 (8)
    DOI 10.1136/jitc-2023-006944, PubMed 37607769

Publications 2022

  1. Bekri S, Rodney-Sandy R, Gruenstein D, Mei A, Bogen B, Castle J, Levey D, Cho HJ (2022)
    Neoantigen vaccine-induced CD4 T cells confer protective immunity in a mouse model of multiple myeloma through activation of CD8 T cells against non-vaccine, tumor-associated antigens
    J Immunother Cancer, 10 (2)
    DOI 10.1136/jitc-2021-003572, PubMed 35190376
  2. Gjesdal BE, Mæland S, Bogen B, Cumming KT, Nesse VC, Torberntsson SMR, Rygh CB (2022)
    Ballistic strength training in adults with cerebral palsy may increase rate of force development in plantar flexors, but transition to walking remains unclear: a case series
    BMC Sports Sci Med Rehabil, 14 (1), 101
    DOI 10.1186/s13102-022-00487-1, PubMed 35659348
  3. Hinke DM, Andersen TK, Gopalakrishnan RP, Skullerud LM, Werninghaus IC, Grødeland G, Fossum E, Braathen R, Bogen B (2022)
    Antigen bivalency of antigen-presenting cell-targeted vaccines increases B cell responses
    Cell Rep, 39 (9), 110901
    DOI 10.1016/j.celrep.2022.110901, PubMed 35649357
  4. Jung K, Jeon YK, Jeong DH, Byun JM, Bogen B, Choi I (2022)
    VSIG4-expressing tumor-associated macrophages impair anti-tumor immunity
    Biochem Biophys Res Commun, 628, 18-24
    DOI 10.1016/j.bbrc.2022.08.055, PubMed 36063598
  5. Lopes R, Caetano J, Barahona F, Pestana C, Ferreira BV, Lourenço D, Queirós AC, Bilreiro C, Shemesh N, Beck HC, Carvalho AS, Matthiesen R, Bogen B, Costa-Silva B, Serre K, Carneiro EA, João C (2022)
    Multiple Myeloma-Derived Extracellular Vesicles Modulate the Bone Marrow Immune Microenvironment
    Front Immunol, 13, 909880
    DOI 10.3389/fimmu.2022.909880, PubMed 35874665
  6. Tesfaye DY, Bobic S, Lysén A, Huszthy PC, Gudjonsson A, Braathen R, Bogen B, Fossum E (2022)
    Targeting Xcr1 on Dendritic Cells Rapidly Induce Th1-Associated Immune Responses That Contribute to Protection Against Influenza Infection
    Front Immunol, 13, 752714
    DOI 10.3389/fimmu.2022.752714, PubMed 35296089

Publications 2021

  1. Andersen TK, Bodin J, Oftung F, Bogen B, Mjaaland S, Grødeland G (2021)
    Pandemic Preparedness Against Influenza: DNA Vaccine for Rapid Relief
    Front Immunol, 12, 747032
    DOI 10.3389/fimmu.2021.747032, PubMed 34691056
  2. Bjerkan L, Visweswaran GRR, Gudjonsson A, Labbé GM, Quinkert D, Pattinson DJ, Spång HCL, Draper SJ, Bogen B, Braathen R (2021)
    APC-Targeted DNA Vaccination Against Reticulocyte-Binding Protein Homolog 5 Induces Plasmodium falciparum-Specific Neutralizing Antibodies and T Cell Responses
    Front Immunol, 12, 720550
    DOI 10.3389/fimmu.2021.720550, PubMed 34733274
  3. He L, Valignat MP, Zhang L, Gelard L, Zhang F, Le Guen V, Audebert S, Camoin L, Fossum E, Bogen B, Wang H, Henri S, Roncagalli R, Theodoly O, Liang Y, Malissen M, Malissen B (2021)
    ARHGAP45 controls naïve T- and B-cell entry into lymph nodes and T-cell progenitor thymus seeding
    EMBO Rep, 22 (4), e52196
    DOI 10.15252/embr.202052196, PubMed 33719206
  4. Høydahl LS, Frigstad T, Rasmussen IB, Øynebråten I, Schjetne KW, Andersen JT, Michaelsen TE, Lunde E, Bogen B, Sandlie I (2021)
    Antibody-mediated delivery of T-cell epitopes to antigen-presenting cells induce strong CD4 and CD8 T-cell responses
    Vaccine, 39 (11), 1583-1592
    DOI 10.1016/j.vaccine.2021.02.012, PubMed 33612340
  5. Lysén A, Gudjonsson A, Tesfaye DY, Bobic S, Bern M, Bogen B, Fossum E (2021)
    Intranasal delivery of a cDC1 targeted influenza vaccine with poly(I:C) enhances T cell responses and protects against influenza infection
    Scand J Immunol, 95 (3), e13128
    DOI 10.1111/sji.13128, PubMed 34923667
  6. Szodoray P, Andersen TK, Heinzelbecker J, Imbery JF, Huszthy PC, Stanford SM, Bogen B, Landsverk OB, Bottini N, Tveita A, Munthe LA, Nakken B (2021)
    Integration of T helper and BCR signals governs enhanced plasma cell differentiation of memory B cells by regulation of CD45 phosphatase activity
    Cell Rep, 36 (6), 109525
    DOI 10.1016/j.celrep.2021.109525, PubMed 34380042
  7. Ziouti F, Rummler M, Steyn B, Thiele T, Seliger A, Duda GN, Bogen B, Willie BM, Jundt F (2021)
    Prevention of Bone Destruction by Mechanical Loading Is Not Enhanced by the Bruton's Tyrosine Kinase Inhibitor CC-292 in Myeloma Bone Disease
    Int J Mol Sci, 22 (8)
    DOI 10.3390/ijms22083840, PubMed 33917250

Publications 2020

  1. Brandwein M, Horev A, Bogen B, Fuks G, Israel A, Shalom G, Pinsk V, Steinberg D, Bentwich Z, Shental N, Meshner S (2020)
    The role of sweat in the composition of skin microbiome: lessons learned from patients with congenital insensitivity to pain with anhidrosis
    J Eur Acad Dermatol Venereol, 34 (4), e183-e186
    DOI 10.1111/jdv.16170, PubMed 31875978
  2. Braathen R, Spång HCL, Hinke DM, Blazevski J, Bobic S, Fossum E, Bogen B (2020)
    A DNA Vaccine That Encodes an Antigen-Presenting Cell-Specific Heterodimeric Protein Protects against Cancer and Influenza
    Mol Ther Methods Clin Dev, 17, 378-392
    DOI 10.1016/j.omtm.2020.01.007, PubMed 32128342
  3. Fossum E, Tesfaye DY, Bobic S, Gudjonsson A, Braathen R, Lahoud MH, Caminschi I, Bogen B (2020)
    Targeting Antigens to Different Receptors on Conventional Type 1 Dendritic Cells Impacts the Immune Response
    J Immunol, 205 (3), 661-673
    DOI 10.4049/jimmunol.1901119, PubMed 32591401
  4. Grødeland G, Baranowska-Hustad M, Abadejos J, Blane TR, Teijaro J, Nemazee D, Bogen B (2020)
    Induction of Cross-Reactive and Protective Antibody Responses After DNA Vaccination With MHCII-Targeted Stem Domain From Influenza Hemagglutinin
    Front Immunol, 11, 431
    DOI 10.3389/fimmu.2020.00431, PubMed 32269566
  5. Haabeth OAW, Hennig K, Fauskanger M, Løset GÅ, Bogen B, Tveita A (2020)
    CD4+ T-cell killing of multiple myeloma cells is mediated by resident bone marrow macrophages
    Blood Adv, 4 (12), 2595-2605
    DOI 10.1182/bloodadvances.2020001434, PubMed 32544236
  6. Kwon M, Kim CG, Lee H, Cho H, Kim Y, Lee EC, Choi SJ, Park J, Seo IH, Bogen B, Song IC, Jo DY, Kim JS, Park SH, Choi I, Choi YS, Shin EC (2020)
    PD-1 Blockade Reinvigorates Bone Marrow CD8+ T Cells from Patients with Multiple Myeloma in the Presence of TGFβ Inhibitors
    Clin Cancer Res, 26 (7), 1644-1655
    DOI 10.1158/1078-0432.CCR-19-0267, PubMed 31941832
  7. Lysén A, Braathen R, Gudjonsson A, Tesfaye DY, Bogen B, Fossum E (2020)
    Author Correction: Dendritic cell targeted Ccl3- and Xcl1-fusion DNA vaccines differ in induced immune responses and optimal delivery site
    Sci Rep, 10 (1), 5944
    DOI 10.1038/s41598-020-62688-3, PubMed 32231213
  8. Rummler M, Ziouti F, Bouchard AL, Brandl A, Duda GN, Bogen B, Beilhack A, Lynch ME, Jundt F, Willie BM (2020)
    Mechanical loading prevents bone destruction and exerts anti-tumor effects in the MOPC315.BM.Luc model of myeloma bone disease
    Acta Biomater, 119, 247-258
    DOI 10.1016/j.actbio.2020.10.041, PubMed 33130307
  9. Ziouti F, Soares AP, Moreno-Jiménez I, Rack A, Bogen B, Cipitria A, Zaslansky P, Jundt F (2020)
    An Early Myeloma Bone Disease Model in Skeletally Mature Mice as a Platform for Biomaterial Characterization of the Extracellular Matrix
    J Oncol, 2020, 3985315
    DOI 10.1155/2020/3985315, PubMed 32684931

Publications 2019

  1. Andersen TK, Huszthy PC, Gopalakrishnan RP, Jacobsen JT, Fauskanger M, Tveita AA, Grødeland G, Bogen B (2019)
    Enhanced germinal center reaction by targeting vaccine antigen to major histocompatibility complex class II molecules
    NPJ Vaccines, 4, 9
    DOI 10.1038/s41541-019-0101-0, PubMed 30775000
  2. Baghdadi M, Ishikawa K, Nakanishi S, Murata T, Umeyama Y, Kobayashi T, Kameda Y, Endo H, Wada H, Bogen B, Yamamoto S, Yamaguchi K, Kasahara I, Iwasaki H, Takahata M, Ibata M, Takahashi S, Goto H, Teshima T, Seino KI (2019)
    A role for IL-34 in osteolytic disease of multiple myeloma
    Blood Adv, 3 (4), 541-551
    DOI 10.1182/bloodadvances.2018020008, PubMed 30782613
  3. Bogen B, Fauskanger M, Haabeth OA, Tveita A (2019)
    CD4+ T cells indirectly kill tumor cells via induction of cytotoxic macrophages in mouse models
    Cancer Immunol Immunother, 68 (11), 1865-1873
    DOI 10.1007/s00262-019-02374-0, PubMed 31448380
  4. Exner ND, Valenzuela JAC, Abou-El-Ardat K, Miletic H, Huszthy PC, Radehaus PM, Schröck E, Bjerkvig R, Kaderali L, Klink B, Nigro JM (2019)
    Deep sequencing of a recurrent oligodendroglioma and the derived xenografts reveals new insights into the evolution of human oligodendroglioma and candidate driver genes
    Oncotarget, 10 (38), 3641-3653
    DOI 10.18632/oncotarget.26950, PubMed 31217899
  5. Grodeland G, Fossum E, Bogen B (2019)
    Targeting of HA to chemokine receptors induces strong and cross-reactive T cell responses after DNA vaccination in pigs
    Vaccine, 38 (6), 1280-1285
    DOI 10.1016/j.vaccine.2019.11.084, PubMed 31836256
  6. Gudjonsson A, Andersen TK, Sundvold-Gjerstad V, Bogen B, Fossum E (2019)
    Endocytosis Deficient Murine Xcl1-Fusion Vaccine Enhances Protective Antibody Responses in Mice
    Front Immunol, 10, 1086
    DOI 10.3389/fimmu.2019.01086, PubMed 31156636
  7. Huszthy PC, Gopalakrishnan RP, Jacobsen JT, Haabeth OAW, Løset GÅ, Braathen R, Schenck K, Tveita AA, Munthe LA, Bogen B (2019)
    B cell receptor ligation induces display of V-region peptides on MHC class II molecules to T cells
    Proc Natl Acad Sci U S A, 116 (51), 25850-25859
    DOI 10.1073/pnas.1902836116, PubMed 31796587
  8. Høglund RA, Torsetnes SB, Lossius A, Bogen B, Homan EJ, Bremel R, Holmøy T (2019)
    Human Cysteine Cathepsins Degrade Immunoglobulin G In Vitro in a Predictable Manner
    Int J Mol Sci, 20 (19)
    DOI 10.3390/ijms20194843, PubMed 31569504
  9. Lysén A, Braathen R, Gudjonsson A, Tesfaye DY, Bogen B, Fossum E (2019)
    Dendritic cell targeted Ccl3- and Xcl1-fusion DNA vaccines differ in induced immune responses and optimal delivery site
    Sci Rep, 9 (1), 1820
    DOI 10.1038/s41598-018-38080-7, PubMed 30755656
  10. Mahalunkar S, Yadav AS, Gorain M, Pawar V, Braathen R, Weiss S, Bogen B, Gosavi SW, Kundu GC (2019)
    Functional design of pH-responsive folate-targeted polymer-coated gold nanoparticles for drug delivery and in vivo therapy in breast cancer
    Int J Nanomedicine, 14, 8285-8302
    DOI 10.2147/IJN.S215142, PubMed 31802866
  11. Mooij P, Grødeland G, Koopman G, Andersen TK, Mortier D, Nieuwenhuis IG, Verschoor EJ, Fagrouch Z, Bogers WM, Bogen B (2019)
    Needle-free delivery of DNA: Targeting of hemagglutinin to MHC class II molecules protects rhesus macaques against H1N1 influenza
    Vaccine, 37 (6), 817-826
    DOI 10.1016/j.vaccine.2018.12.049, PubMed 30638800
  12. Tesfaye DY, Gudjonsson A, Bogen B, Fossum E (2019)
    Targeting Conventional Dendritic Cells to Fine-Tune Antibody Responses
    Front Immunol, 10, 1529
    DOI 10.3389/fimmu.2019.01529, PubMed 31333661

Publications 2018

  1. Abrahamsen G, Sundvold-Gjerstad V, Habtamu M, Bogen B, Spurkland A (2018)
    Polarity of CD4+ T cells towards the antigen presenting cell is regulated by the Lck adapter TSAd
    Sci Rep, 8 (1), 13319
    DOI 10.1038/s41598-018-31510-6, PubMed 30190583
  2. Anderson AM, Baranowska-Hustad M, Braathen R, Grodeland G, Bogen B (2018)
    Simultaneous Targeting of Multiple Hemagglutinins to APCs for Induction of Broad Immunity against Influenza
    J Immunol, 200 (6), 2057-2066
    DOI 10.4049/jimmunol.1701088, PubMed 29427414
  3. Brizić I, Šušak B, Arapović M, Huszthy PC, Hiršl L, Kveštak D, Juranić Lisnić V, Golemac M, Pernjak Pugel E, Tomac J, Oxenius A, Britt WJ, Arapović J, Krmpotić A, Jonjić S (2018)
    Brain-resident memory CD8+ T cells induced by congenital CMV infection prevent brain pathology and virus reactivation
    Eur J Immunol, 48 (6), 950-964
    DOI 10.1002/eji.201847526, PubMed 29500823
  4. Braathen R, Spång HCL, Lindeberg MM, Fossum E, Grødeland G, Fredriksen AB, Bogen B (2018)
    The Magnitude and IgG Subclass of Antibodies Elicited by Targeted DNA Vaccines Are Influenced by Specificity for APC Surface Molecules
    Immunohorizons, 2 (1), 38-53
    DOI 10.4049/immunohorizons.1700038, PubMed 31022690
  5. Fauskanger M, Haabeth OAW, Skjeldal FM, Bogen B, Tveita AA (2018)
    Tumor Killing by CD4+ T Cells Is Mediated via Induction of Inducible Nitric Oxide Synthase-Dependent Macrophage Cytotoxicity
    Front Immunol, 9, 1684
    DOI 10.3389/fimmu.2018.01684, PubMed 30083157
  6. Haabeth OAW, Fauskanger M, Manzke M, Lundin KU, Corthay A, Bogen B, Tveita AA (2018)
    CD4+ T-cell-Mediated Rejection of MHC Class II-Positive Tumor Cells Is Dependent on Antigen Secretion and Indirect Presentation on Host APCs
    Cancer Res, 78 (16), 4573-4585
    DOI 10.1158/0008-5472.CAN-17-2426, PubMed 29752262

Publications 2017

  1. Andersen TK, Zhou F, Cox R, Bogen B, Grødeland G (2017)
    A DNA Vaccine That Targets Hemagglutinin to Antigen-Presenting Cells Protects Mice against H7 Influenza
    J Virol, 91 (23)
    DOI 10.1128/JVI.01340-17, PubMed 28931687
  2. Deloizy C, Fossum E, Barnier-Quer C, Urien C, Chrun T, Duval A, Codjovi M, Bouguyon E, Maisonnasse P, Hervé PL, Barc C, Boulesteix O, Pezant J, Chevalier C, Collin N, Dalod M, Bogen B, Bertho N, Schwartz-Cornil I (2017)
    The anti-influenza M2e antibody response is promoted by XCR1 targeting in pig skin
    Sci Rep, 7 (1), 7639
    DOI 10.1038/s41598-017-07372-9, PubMed 28794452
  3. Gudjonsson A, Lysén A, Balan S, Sundvold-Gjerstad V, Arnold-Schrauf C, Richter L, Bækkevold ES, Dalod M, Bogen B, Fossum E (2017)
    Targeting Influenza Virus Hemagglutinin to Xcr1+ Dendritic Cells in the Absence of Receptor-Mediated Endocytosis Enhances Protective Antibody Responses
    J Immunol, 198 (7), 2785-2795
    DOI 10.4049/jimmunol.1601881, PubMed 28228559
  4. Høglund RA, Lossius A, Johansen JN, Homan J, Benth JŠ, Robins H, Bogen B, Bremel RD, Holmøy T (2017)
    In Silico Prediction Analysis of Idiotope-Driven T-B Cell Collaboration in Multiple Sclerosis
    Front Immunol, 8, 1255
    DOI 10.3389/fimmu.2017.01255, PubMed 29038659
  5. Park BM, Kim EJ, Nam HJ, Zhang D, Bae CH, Kang M, Kim H, Lee W, Bogen B, Lim SK (2017)
    Cyclized Oligopeptide Targeting LRP5/6-DKK1 Interaction Reduces the Growth of Tumor Burden in a Multiple Myeloma Mouse Model
    Yonsei Med J, 58 (3), 505-513
    DOI 10.3349/ymj.2017.58.3.505, PubMed 28332354
  6. Primon M, Huszthy PC, Motaln H, Talasila KM, Miletic H, Atai NA, Bjerkvig R, Lah Turnšek T (2017)
    Cathepsin L silencing increases As2O3 toxicity in malignantly transformed pilocytic astrocytoma MPA58 cells by activating caspases 3/7
    Exp Cell Res, 356 (1), 64-73
    DOI 10.1016/j.yexcr.2017.04.013, PubMed 28412241
  7. Wang D, Fløisand Y, Myklebust CV, Bürgler S, Parente-Ribes A, Hofgaard PO, Bogen B, Taskén K, Tjønnfjord GE, Schjesvold F, Dalgaard J, Tveita A, Munthe LA (2017)
    Autologous bone marrow Th cells can support multiple myeloma cell proliferation in vitro and in xenografted mice
    Leukemia, 31 (10), 2114-2121
    DOI 10.1038/leu.2017.69, PubMed 28232741

Publications 2016

  1. Andersen AN, Landsverk OJ, Simonsen A, Bogen B, Corthay A, Øynebråten I (2016)
    Coupling of HIV-1 Antigen to the Selective Autophagy Receptor SQSTM1/p62 Promotes T-Cell-Mediated Immunity
    Front Immunol, 7, 167
    DOI 10.3389/fimmu.2016.00167, PubMed 27242780
  2. Ardouin L, Luche H, Chelbi R, Carpentier S, Shawket A, Montanana Sanchis F, Santa Maria C, Grenot P, Alexandre Y, Grégoire C, Fries A, Vu Manh TP, Tamoutounour S, Crozat K, Tomasello E, Jorquera A, Fossum E, Bogen B, Azukizawa H, Bajenoff M, Henri S, Dalod M, Malissen B (2016)
    Broad and Largely Concordant Molecular Changes Characterize Tolerogenic and Immunogenic Dendritic Cell Maturation in Thymus and Periphery
    Immunity, 45 (2), 305-18
    DOI 10.1016/j.immuni.2016.07.019, PubMed 27533013
  3. Bartee E, Bartee MY, Bogen B, Yu XZ (2016)
    Systemic therapy with oncolytic myxoma virus cures established residual multiple myeloma in mice
    Mol Ther Oncolytics, 3, 16032
    DOI 10.1038/mto.2016.32, PubMed 27933316
  4. Deloizy C, Bouguyon E, Fossum E, Sebo P, Osicka R, Bole A, Pierres M, Biacchesi S, Dalod M, Bogen B, Bertho N, Schwartz-Cornil I (2016)
    Expanding the tools for identifying mononuclear phagocyte subsets in swine: Reagents to porcine CD11c and XCR1
    Dev Comp Immunol, 65, 31-40
    DOI 10.1016/j.dci.2016.06.015, PubMed 27345169
  5. Grodeland G, Fredriksen AB, Løset GÅ, Vikse E, Fugger L, Bogen B (2016)
    Antigen Targeting to Human HLA Class II Molecules Increases Efficacy of DNA Vaccination
    J Immunol, 197 (9), 3575-3585
    DOI 10.4049/jimmunol.1600893, PubMed 27671110
  6. Guilliams M, Dutertre CA, Scott CL, McGovern N, Sichien D, Chakarov S, Van Gassen S, Chen J, Poidinger M, De Prijck S, Tavernier SJ, Low I, Irac SE, Mattar CN, Sumatoh HR, Low GHL, Chung TJK, Chan DKH, Tan KK, Hon TLK, Fossum E, Bogen B, Choolani M, Chan JKY, Larbi A et al. (2016)
    Unsupervised High-Dimensional Analysis Aligns Dendritic Cells across Tissues and Species
    Immunity, 45 (3), 669-684
    DOI 10.1016/j.immuni.2016.08.015, PubMed 27637149
  7. Lambert L, Kinnear E, McDonald JU, Grodeland G, Bogen B, Stubsrud E, Lindeberg MM, Fredriksen AB, Tregoning JS (2016)
    DNA Vaccines Encoding Antigen Targeted to MHC Class II Induce Influenza-Specific CD8(+) T Cell Responses, Enabling Faster Resolution of Influenza Disease
    Front Immunol, 7, 321
    DOI 10.3389/fimmu.2016.00321, PubMed 27602032
  8. Lilly CL, Villa NY, Lemos de Matos A, Ali HM, Dhillon JS, Hofland T, Rahman MM, Chan W, Bogen B, Cogle C, McFadden G (2016)
    Ex Vivo Oncolytic Virotherapy with Myxoma Virus Arms Multiple Allogeneic Bone Marrow Transplant Leukocytes to Enhance Graft versus Tumor
    Mol Ther Oncolytics, 4, 31-40
    DOI 10.1016/j.omto.2016.12.002, PubMed 28345022
  9. Lorvik KB, Hammarström C, Fauskanger M, Haabeth OA, Zangani M, Haraldsen G, Bogen B, Corthay A (2016)
    Adoptive Transfer of Tumor-Specific Th2 Cells Eradicates Tumors by Triggering an In Situ Inflammatory Immune Response
    Cancer Res, 76 (23), 6864-6876
    DOI 10.1158/0008-5472.CAN-16-1219, PubMed 27634753
  10. Tveita A, Fauskanger M, Bogen B, Haabeth OA (2016)
    Tumor-specific CD4+ T cells eradicate myeloma cells genetically deficient in MHC class II display
    Oncotarget, 7 (41), 67175-67182
    DOI 10.18632/oncotarget.11946, PubMed 27626487
  11. Zhou P, Chionh YT, Irac SE, Ahn M, Jia Ng JH, Fossum E, Bogen B, Ginhoux F, Irving AT, Dutertre CA, Wang LF (2016)
    Unlocking bat immunology: establishment of Pteropus alecto bone marrow-derived dendritic cells and macrophages
    Sci Rep, 6, 38597
    DOI 10.1038/srep38597, PubMed 27934903

Publications 2015

  1. Baranowska M, Hauge AG, Hoornaert C, Bogen B, Grødeland G (2015)
    Targeting of nucleoprotein to chemokine receptors by DNA vaccination results in increased CD8(+)-mediated cross protection against influenza
    Vaccine, 33 (49), 6988-96
    DOI 10.1016/j.vaccine.2015.08.094, PubMed 26387432
  2. Grødeland G, Bogen B (2015)
    Efficient vaccine against pandemic influenza: combining DNA vaccination and targeted delivery to MHC class II molecules
    Expert Rev Vaccines, 14 (6), 805-14
    DOI 10.1586/14760584.2015.1029919, PubMed 25818107
  3. Grødeland G, Fossum E, Bogen B (2015)
    Polarizing T and B Cell Responses by APC-Targeted Subunit Vaccines
    Front Immunol, 6, 367
    DOI 10.3389/fimmu.2015.00367, PubMed 26257735
  4. Huszthy PC, Sakariassen PØ, Espedal H, Brokstad KA, Bjerkvig R, Miletic H (2015)
    Engraftment of Human Glioblastoma Cells in Immunocompetent Rats through Acquired Immunosuppression
    PLoS One, 10 (8), e0136089
    DOI 10.1371/journal.pone.0136089, PubMed 26291724
  5. Huszthy PC, Sakariassen PØ, Espedal H, Brokstad KA, Bjerkvig R, Miletic H (2015)
    Correction: Engraftment of Human Glioblastoma Cells in Immunocompetent Rats through Acquired Immunosuppression
    PLoS One, 10 (10), e0140303
    DOI 10.1371/journal.pone.0140303, PubMed 26431334
  6. Haabeth OA, Lorvik KB, Yagita H, Bogen B, Corthay A (2015)
    Interleukin-1 is required for cancer eradication mediated by tumor-specific Th1 cells
    Oncoimmunology, 5 (1), e1039763
    DOI 10.1080/2162402X.2015.1039763, PubMed 26942052
  7. Haabeth OA, Tveita A, Fauskanger M, Hennig K, Hofgaard PO, Bogen B (2015)
    Idiotype-specific CD4(+) T cells eradicate disseminated myeloma
    Leukemia, 30 (5), 1216-20
    DOI 10.1038/leu.2015.278, PubMed 26449664
  8. Kikuchi J, Koyama D, Wada T, Izumi T, Hofgaard PO, Bogen B, Furukawa Y (2015)
    Phosphorylation-mediated EZH2 inactivation promotes drug resistance in multiple myeloma
    J Clin Invest, 125 (12), 4375-90
    DOI 10.1172/JCI80325, PubMed 26517694
  9. Kulkarni U, Karsten CM, Kohler T, Hammerschmidt S, Bommert K, Tiburzy B, Meng L, Thieme L, Recke A, Ludwig RJ, Pollok K, Kalies K, Bogen B, Boettcher M, Kamradt T, Hauser AE, Langer C, Huber-Lang M, Finkelman FD, Köhl J, Wong DM, Manz RA (2015)
    IL-10 mediates plasmacytosis-associated immunodeficiency by inhibiting complement-mediated neutrophil migration
    J Allergy Clin Immunol, 137 (5), 1487-1497.e6
    DOI 10.1016/j.jaci.2015.10.018, PubMed 26653800
  10. Matthes T, Manfroi B, Zeller A, Dunand-Sauthier I, Bogen B, Huard B (2015)
    Autocrine amplification of immature myeloid cells by IL-6 in multiple myeloma-infiltrated bone marrow
    Leukemia, 29 (9), 1882-90
    DOI 10.1038/leu.2015.145, PubMed 26159051
  11. Nagy G, Huszthy PC, Fossum E, Konttinen Y, Nakken B, Szodoray P (2015)
    Selected Aspects in the Pathogenesis of Autoimmune Diseases
    Mediators Inflamm, 2015, 351732
    DOI 10.1155/2015/351732, PubMed 26300591
  12. Nakken B, Nagy G, Huszthy PC, Fossum E, Konttinen Y, Szodoray P (2015)
    Inflammatory Mediators in Autoimmunity and Systemic Autoimmune Diseases
    Mediators Inflamm, 2015, 878712
    DOI 10.1155/2015/878712, PubMed 26346773
  13. Parente-Ribes A, Skånland SS, Bürgler S, Os A, Wang D, Bogen B, Tjønnfjord GE, Taskén K, Munthe LA (2015)
    Spleen tyrosine kinase inhibitors reduce CD40L-induced proliferation of chronic lymphocytic leukemia cells but not normal B cells
    Haematologica, 101 (2), e59-62
    DOI 10.3324/haematol.2015.135590, PubMed 26589914
  14. Terhorst D, Fossum E, Baranska A, Tamoutounour S, Malosse C, Garbani M, Braun R, Lechat E, Crameri R, Bogen B, Henri S, Malissen B (2015)
    Laser-assisted intradermal delivery of adjuvant-free vaccines targeting XCR1+ dendritic cells induces potent antitumoral responses
    J Immunol, 194 (12), 5895-902
    DOI 10.4049/jimmunol.1500564, PubMed 25941327
  15. Tveita AA, Schjesvold F, Haabeth OA, Fauskanger M, Bogen B (2015)
    Tumors Escape CD4+ T-cell-Mediated Immunosurveillance by Impairing the Ability of Infiltrating Macrophages to Indirectly Present Tumor Antigens
    Cancer Res, 75 (16), 3268-78
    DOI 10.1158/0008-5472.CAN-14-3640, PubMed 26038231
  16. Aas-Hanssen K, Thompson KM, Bogen B, Munthe LA (2015)
    Systemic Lupus Erythematosus: Molecular Mimicry between Anti-dsDNA CDR3 Idiotype, Microbial and Self Peptides-As Antigens for Th Cells
    Front Immunol, 6, 382
    DOI 10.3389/fimmu.2015.00382, PubMed 26284067

Publications 2014

  1. Balan S, Ollion V, Colletti N, Chelbi R, Montanana-Sanchis F, Liu H, Vu Manh TP, Sanchez C, Savoret J, Perrot I, Doffin AC, Fossum E, Bechlian D, Chabannon C, Bogen B, Asselin-Paturel C, Shaw M, Soos T, Caux C, Valladeau-Guilemond J, Dalod M (2014)
    Human XCR1+ dendritic cells derived in vitro from CD34+ progenitors closely resemble blood dendritic cells, including their adjuvant responsiveness, contrary to monocyte-derived dendritic cells
    J Immunol, 193 (4), 1622-35
    DOI 10.4049/jimmunol.1401243, PubMed 25009205
  2. Binsfeld M, Beguin Y, Belle L, Otjacques E, Hannon M, Briquet A, Heusschen R, Drion P, Zilberberg J, Bogen B, Baron F, Caers J (2014)
    Establishment of a murine graft-versus-myeloma model using allogeneic stem cell transplantation
    PLoS One, 9 (11), e113764
    DOI 10.1371/journal.pone.0113764, PubMed 25415267
  3. Bürgler S, Gimeno A, Parente-Ribes A, Wang D, Os A, Devereux S, Jebsen P, Bogen B, Tjønnfjord GE, Munthe LA (2014)
    Chronic lymphocytic leukemia cells express CD38 in response to Th1 cell-derived IFN-γ by a T-bet-dependent mechanism
    J Immunol, 194 (2), 827-35
    DOI 10.4049/jimmunol.1401350, PubMed 25505279
  4. Dutertre CA, Jourdain JP, Rancez M, Amraoui S, Fossum E, Bogen B, Sanchez C, Couëdel-Courteille A, Richard Y, Dalod M, Feuillet V, Cheynier R, Hosmalin A (2014)
    TLR3-responsive, XCR1+, CD141(BDCA-3)+/CD8α+-equivalent dendritic cells uncovered in healthy and simian immunodeficiency virus-infected rhesus macaques
    J Immunol, 192 (10), 4697-708
    DOI 10.4049/jimmunol.1302448, PubMed 24740505
  5. Fossum E, Grødeland G, Terhorst D, Tveita AA, Vikse E, Mjaaland S, Henri S, Malissen B, Bogen B (2014)
    Vaccine molecules targeting Xcr1 on cross-presenting DCs induce protective CD8+ T-cell responses against influenza virus
    Eur J Immunol, 45 (2), 624-35
    DOI 10.1002/eji.201445080, PubMed 25410055
  6. Haabeth OA, Tveita AA, Fauskanger M, Schjesvold F, Lorvik KB, Hofgaard PO, Omholt H, Munthe LA, Dembic Z, Corthay A, Bogen B (2014)
    How Do CD4(+) T Cells Detect and Eliminate Tumor Cells That Either Lack or Express MHC Class II Molecules?
    Front Immunol, 5, 174
    DOI 10.3389/fimmu.2014.00174, PubMed 24782871
  7. Jacobsen J, Haabeth OA, Tveita AA, Schjetne KW, Munthe LA, Bogen B (2014)
    Naive idiotope-specific B and T cells collaborate efficiently in the absence of dendritic cells
    J Immunol, 192 (9), 4174-83
    DOI 10.4049/jimmunol.1302359, PubMed 24706724
  8. Løvås TO, Bruusgaard JC, Øynebråten I, Gundersen K, Bogen B (2014)
    DNA vaccines: MHC II-targeted vaccine protein produced by transfected muscle fibres induces a local inflammatory cell infiltrate in mice
    PLoS One, 9 (10), e108069
    DOI 10.1371/journal.pone.0108069, PubMed 25299691
  9. Ruffini PA, Os A, Dolcetti R, Tjønnfjord GE, Munthe LA, Bogen B (2014)
    Targeted DNA vaccines eliciting crossreactive anti-idiotypic antibody responses against human B cell malignancies in mice
    J Transl Med, 12, 207
    DOI 10.1186/1479-5876-12-207, PubMed 25059102
  10. Schwarzer R, Nickel N, Godau J, Willie BM, Duda GN, Schwarzer R, Cirovic B, Leutz A, Manz R, Bogen B, Dörken B, Jundt F (2014)
    Notch pathway inhibition controls myeloma bone disease in the murine MOPC315.BM model
    Blood Cancer J, 4 (6), e217
    DOI 10.1038/bcj.2014.37, PubMed 24927406
  11. Slavuljica I, Kveštak D, Huszthy PC, Kosmac K, Britt WJ, Jonjić S (2014)
    Immunobiology of congenital cytomegalovirus infection of the central nervous system—the murine cytomegalovirus model
    Cell Mol Immunol, 12 (2), 180-91
    DOI 10.1038/cmi.2014.51, PubMed 25042632
  12. Tveita AA, Haabeth OA, Bogen B (2014)
    Limitations of bystander killing in Th1/M1 immune responses against a secreted tumor antigen
    Oncoimmunology, 3 (9), e954953
    DOI 10.4161/21624011.2014.954953, PubMed 25941607
  13. Tveita AA, Schjesvold FH, Sundnes O, Haabeth OA, Haraldsen G, Bogen B (2014)
    Indirect CD4+ T-cell-mediated elimination of MHC II(NEG) tumor cells is spatially restricted and fails to prevent escape of antigen-negative cells
    Eur J Immunol, 44 (9), 2625-37
    DOI 10.1002/eji.201444659, PubMed 24846412
  14. Wong D, Winter O, Hartig C, Siebels S, Szyska M, Tiburzy B, Meng L, Kulkarni U, Fähnrich A, Bommert K, Bargou R, Berek C, Chu VT, Bogen B, Jundt F, Manz RA (2014)
    Eosinophils and megakaryocytes support the early growth of murine MOPC315 myeloma cells in their bone marrow niches
    PLoS One, 9 (10), e109018
    DOI 10.1371/journal.pone.0109018, PubMed 25272036
  15. Øynebråten I, Hinkula J, Fredriksen AB, Bogen B (2014)
    Increased generation of HIV-1 gp120-reactive CD8+ T cells by a DNA vaccine construct encoding the chemokine CCL3
    PLoS One, 9 (8), e104814
    DOI 10.1371/journal.pone.0104814, PubMed 25122197
  16. Aas-Hanssen K, Funderud A, Thompson KM, Bogen B, Munthe LA (2014)
    Idiotype-specific Th cells support oligoclonal expansion of anti-dsDNA B cells in mice with lupus
    J Immunol, 193 (6), 2691-8
    DOI 10.4049/jimmunol.1400640, PubMed 25127856

Publications 2013

  1. Daphu I, Sundstrøm T, Horn S, Huszthy PC, Niclou SP, Sakariassen PØ, Immervoll H, Miletic H, Bjerkvig R, Thorsen F (2013)
    In vivo animal models for studying brain metastasis: value and limitations
    Clin Exp Metastasis, 30 (5), 695-710
    DOI 10.1007/s10585-013-9566-9, PubMed 23322381
  2. Frigstad T, Løset GÅ, Sandlie I, Bogen B (2013)
    A public T cell receptor recognized by a monoclonal antibody specific for the D-J junction of the β-chain
    Scand J Immunol, 78 (4), 345-51
    DOI 10.1111/sji.12098, PubMed 23841814
  3. Griffiths SJ, Koegl M, Boutell C, Zenner HL, Crump CM, Pica F, Gonzalez O, Friedel CC, Barry G, Martin K, Craigon MH, Chen R, Kaza LN, Fossum E, Fazakerley JK, Efstathiou S, Volpi A, Zimmer R, Ghazal P, Haas J (2013)
    A systematic analysis of host factors reveals a Med23-interferon-λ regulatory axis against herpes simplex virus type 1 replication
    PLoS Pathog, 9 (8), e1003514
    DOI 10.1371/journal.ppat.1003514, PubMed 23950709
  4. Grodeland G, Mjaaland S, Roux KH, Fredriksen AB, Bogen B (2013)
    DNA vaccine that targets hemagglutinin to MHC class II molecules rapidly induces antibody-mediated protection against influenza
    J Immunol, 191 (6), 3221-31
    DOI 10.4049/jimmunol.1300504, PubMed 23956431
  5. Grødeland G, Mjaaland S, Tunheim G, Fredriksen AB, Bogen B (2013)
    The specificity of targeted vaccines for APC surface molecules influences the immune response phenotype
    PLoS One, 8 (11), e80008
    DOI 10.1371/journal.pone.0080008, PubMed 24244595
  6. Gunnarsen KS, Kristinsson SG, Justesen S, Frigstad T, Buus S, Bogen B, Sandlie I, Løset GÅ (2013)
    Chaperone-assisted thermostability engineering of a soluble T cell receptor using phage display
    Sci Rep, 3, 1162
    DOI 10.1038/srep01162, PubMed 23362461
  7. Hong S, Lee H, Jung K, Lee SM, Lee SJ, Jun HJ, Kim Y, Song H, Bogen B, Choi I (2013)
    Tumor cells loaded with α-galactosylceramide promote therapeutic NKT-dependent anti-tumor immunity in multiple myeloma
    Immunol Lett, 156 (1-2), 132-9
    DOI 10.1016/j.imlet.2013.10.002, PubMed 24148970
  8. Jacobsen JT, Sundvold-Gjerstad V, Skjeldal FM, Andersen JT, Abrahamsen G, Bakke O, Spurkland A, Bogen B (2013)
    B-cell tolerance to the B-cell receptor variable regions
    Eur J Immunol, 43 (10), 2577-87
    DOI 10.1002/eji.201243203, PubMed 23839948
  9. Jarzabek MA, Huszthy PC, Skaftnesmo KO, McCormack E, Dicker P, Prehn JH, Bjerkvig R, Byrne AT (2013)
    In vivo bioluminescence imaging validation of a human biopsy-derived orthotopic mouse model of glioblastoma multiforme
    Mol Imaging, 12 (3), 161-72
    PubMed 23490442
  10. Jarzabek MA, Huszthy PC, Skaftnesmo KO, McCormack E, Dicker P, Prehn JHM, Bjerkvig R, Byrne AT (2013)
    In Vivo Bioluminescence Imaging Validation of a Human Biopsy-Derived Orthotopic Mouse Model of Glioblastoma Multiforme
    Mol. Imaging, 12 (3)
    DOI 10.2310/7290.2012.00029
  11. Klink B, Miletic H, Stieber D, Huszthy PC, Campos Valenzuela JA, Balss J, Wang J, Schubert M, Sakariassen PØ, Sundstrøm T, Torsvik A, Aarhus M, Mahesparan R, von Deimling A, Kaderali L, Niclou SP, Schröck E, Bjerkvig R, Nigro JM (2013)
    A novel, diffusely infiltrative xenograft model of human anaplastic oligodendroglioma with mutations in FUBP1, CIC, and IDH1
    PLoS One, 8 (3), e59773
    DOI 10.1371/journal.pone.0059773, PubMed 23527265
  12. Lorvik KB, Haabeth OA, Clancy T, Bogen B, Corthay A (2013)
    Molecular profiling of tumor-specific TH1 cells activated in vivo
    Oncoimmunology, 2 (5), e24383
    DOI 10.4161/onci.24383, PubMed 23762808
  13. Os A, Bürgler S, Ribes AP, Funderud A, Wang D, Thompson KM, Tjønnfjord GE, Bogen B, Munthe LA (2013)
    Chronic lymphocytic leukemia cells are activated and proliferate in response to specific T helper cells
    Cell Rep, 4 (3), 566-77
    DOI 10.1016/j.celrep.2013.07.011, PubMed 23933259
  14. Primon M, Huszthy PC, Motaln H, Talasila KM, Torkar A, Bjerkvig R, Lah Turnšek T (2013)
    Cathepsin L silencing enhances arsenic trioxide mediated in vitro cytotoxicity and apoptosis in glioblastoma U87MG spheroids
    Exp Cell Res, 319 (17), 2637-48
    DOI 10.1016/j.yexcr.2013.08.011, PubMed 23968587
  15. Talasila KM, Soentgerath A, Euskirchen P, Rosland GV, Wang J, Huszthy PC, Prestegarden L, Skaftnesmo KO, Sakariassen PØ, Eskilsson E, Stieber D, Keunen O, Brekka N, Moen I, Nigro JM, Vintermyr OK, Lund-Johansen M, Niclou S, Mørk SJ, Enger PO, Bjerkvig R, Miletic H (2013)
    EGFR wild-type amplification and activation promote invasion and development of glioblastoma independent of angiogenesis
    Acta Neuropathol, 125 (5), 683-98
    DOI 10.1007/s00401-013-1101-1, PubMed 23429996

Publications 2012

  1. Berge T, Grønningsæter IH, Lorvik KB, Abrahamsen G, Granum S, Sundvold-Gjerstad V, Corthay A, Bogen B, Spurkland A (2012)
    SH2D2A modulates T cell mediated protection to a B cell derived tumor in transgenic mice
    PLoS One, 7 (10), e48239
    DOI 10.1371/journal.pone.0048239, PubMed 23144743
  2. Fredriksen AB, Sandlie I, Bogen B (2012)
    Targeted DNA vaccines for enhanced induction of idiotype-specific B and T cells
    Front Oncol, 2, 154
    DOI 10.3389/fonc.2012.00154, PubMed 23115759
  3. Gole B, Huszthy PC, Popović M, Jeruc J, Ardebili YS, Bjerkvig R, Lah TT (2012)
    The regulation of cysteine cathepsins and cystatins in human gliomas
    Int J Cancer, 131 (8), 1779-89
    DOI 10.1002/ijc.27453, PubMed 22287159
  4. Heimberger T, Andrulis M, Riedel S, Stühmer T, Schraud H, Beilhack A, Bumm T, Bogen B, Einsele H, Bargou RC, Chatterjee M (2012)
    The heat shock transcription factor 1 as a potential new therapeutic target in multiple myeloma
    Br J Haematol, 160 (4), 465-76
    DOI 10.1111/bjh.12164, PubMed 23252346
  5. Hofgaard PO, Jodal HC, Bommert K, Huard B, Caers J, Carlsen H, Schwarzer R, Schünemann N, Jundt F, Lindeberg MM, Bogen B (2012)
    A novel mouse model for multiple myeloma (MOPC315.BM) that allows noninvasive spatiotemporal detection of osteolytic disease
    PLoS One, 7 (12), e51892
    DOI 10.1371/journal.pone.0051892, PubMed 23284805
  6. Huszthy PC, Daphu I, Niclou SP, Stieber D, Nigro JM, Sakariassen PØ, Miletic H, Thorsen F, Bjerkvig R (2012)
    In vivo models of primary brain tumors: pitfalls and perspectives
    Neuro Oncol, 14 (8), 979-93
    DOI 10.1093/neuonc/nos135, PubMed 22679124
  7. Haabeth OA, Bogen B, Corthay A (2012)
    A model for cancer-suppressive inflammation
    Oncoimmunology, 1 (7), 1146-1155
    DOI 10.4161/onci.21542, PubMed 23170261
  8. Lorvik KB, Bogen B, Corthay A (2012)
    Fingolimod blocks immunosurveillance of myeloma and B-cell lymphoma resulting in cancer development in mice
    Blood, 119 (9), 2176-7
    DOI 10.1182/blood-2011-10-388892, PubMed 22383793
  9. Najbauer J, Huszthy PC, Barish ME, Garcia E, Metz MZ, Myers SM, Gutova M, Frank RT, Miletic H, Kendall SE, Glackin CA, Bjerkvig R, Aboody KS (2012)
    Cellular host responses to gliomas
    PLoS One, 7 (4), e35150
    DOI 10.1371/journal.pone.0035150, PubMed 22539956
  10. Nilssen NR, Frigstad T, Pollmann S, Roos N, Bogen B, Sandlie I, Løset GÅ (2012)
    DeltaPhage--a novel helper phage for high-valence pIX phagemid display
    Nucleic Acids Res, 40 (16), e120
    DOI 10.1093/nar/gks341, PubMed 22539265
  11. Rasmussen IB, Oynebråten I, Høydahl LS, Flobakk M, Lunde E, Michaelsen TE, Bogen B, Sandlie I (2012)
    CD40/APC-specific antibodies with three T-cell epitopes loaded in the constant domains induce CD4+ T-cell responses
    Protein Eng Des Sel, 25 (3), 89-96
    DOI 10.1093/protein/gzr063, PubMed 22233931
  12. Riedel SS, Mottok A, Brede C, Bäuerlein CA, Jordán Garrote AL, Ritz M, Mattenheimer K, Rosenwald A, Einsele H, Bogen B, Beilhack A (2012)
    Non-invasive imaging provides spatiotemporal information on disease progression and response to therapy in a murine model of multiple myeloma
    PLoS One, 7 (12), e52398
    DOI 10.1371/journal.pone.0052398, PubMed 23300660
  13. Spång HC, Braathen R, Bogen B (2012)
    Heterodimeric barnase-barstar vaccine molecules: influence of one versus two targeting units specific for antigen presenting cells
    PLoS One, 7 (9), e45393
    DOI 10.1371/journal.pone.0045393, PubMed 23028981
  14. Øynebråten I, Løvås TO, Thompson K, Bogen B (2012)
    Generation of antibody-producing hybridomas following one single immunization with a targeted DNA vaccine
    Scand J Immunol, 75 (4), 379-88
    DOI 10.1111/j.1365-3083.2011.02639.x, PubMed 21955209

Publications 2011

  1. Bannoehr J, Ben Zakour NL, Reglinski M, Inglis NF, Prabhakaran S, Fossum E, Smith DG, Wilson GJ, Cartwright RA, Haas J, Hook M, van den Broek AH, Thoday KL, Fitzgerald JR (2011)
    Genomic and surface proteomic analysis of the canine pathogen Staphylococcus pseudintermedius reveals proteins that mediate adherence to the extracellular matrix
    Infect Immun, 79 (8), 3074-86
    DOI 10.1128/IAI.00137-11, PubMed 21576333
  2. Bogen B (2011)
    Lymphoma invisibility-vaccination-attack?
    Blood, 117 (5), 1437-8
    DOI 10.1182/blood-2010-11-318469, PubMed 21292780
  3. Bogen B (2011)
    Welcome to the 40th Scandinavian Society for Immunology meeting at Geilo, Norway
    Scand. J. Immunol., 73 (4), 267
    DOI 10.1111/j.1365-3083.2011.02509.x
  4. Corthay A, Lorvik KB, Bogen B (2011)
    Is secretion of tumour-specific antigen important for cancer eradication by CD4(+) T cells?--Implications for cancer immunotherapy by adoptive T cell transfer
    Scand J Immunol, 73 (6), 527-30
    DOI 10.1111/j.1365-3083.2011.02558.x, PubMed 21388431
  5. Crozat K, Tamoutounour S, Vu Manh TP, Fossum E, Luche H, Ardouin L, Guilliams M, Azukizawa H, Bogen B, Malissen B, Henri S, Dalod M (2011)
    Cutting edge: expression of XCR1 defines mouse lymphoid-tissue resident and migratory dendritic cells of the CD8α+ type
    J Immunol, 187 (9), 4411-5
    DOI 10.4049/jimmunol.1101717, PubMed 21948982
  6. Euskirchen P, Skaftnesmo KO, Huszthy PC, Brekkå N, Bjerkvig R, Jacobs AH, Miletic H (2011)
    NUMB does not impair growth and differentiation status of experimental gliomas
    Exp Cell Res, 317 (20), 2864-73
    DOI 10.1016/j.yexcr.2011.09.002, PubMed 21939656
  7. Follin-Arbelet V, Hofgaard PO, Hauglin H, Naderi S, Sundan A, Blomhoff R, Bogen B, Blomhoff HK (2011)
    Cyclic AMP induces apoptosis in multiple myeloma cells and inhibits tumor development in a mouse myeloma model
    BMC Cancer, 11, 301
    DOI 10.1186/1471-2407-11-301, PubMed 21767374
  8. Frøyland M, Ruffini PA, Thompson KM, Gedde-Dahl T, Fredriksen AB, Bogen B (2011)
    Targeted idiotype-fusion DNA vaccines for human multiple myeloma: preclinical testing
    Eur J Haematol, 86 (5), 385-95
    DOI 10.1111/j.1600-0609.2011.01590.x, PubMed 21332794
  9. Haabeth OA, Lorvik KB, Hammarström C, Donaldson IM, Haraldsen G, Bogen B, Corthay A (2011)
    Inflammation driven by tumour-specific Th1 cells protects against B-cell cancer
    Nat Commun, 2, 240
    DOI 10.1038/ncomms1239, PubMed 21407206
  10. Løset GÅ, Bogen B, Sandlie I (2011)
    Expanding the versatility of phage display I: efficient display of peptide-tags on protein VII of the filamentous phage
    PLoS One, 6 (2), e14702
    DOI 10.1371/journal.pone.0014702, PubMed 21390217
  11. Løset GÅ, Roos N, Bogen B, Sandlie I (2011)
    Expanding the versatility of phage display II: improved affinity selection of folded domains on protein VII and IX of the filamentous phage
    PLoS One, 6 (2), e17433
    DOI 10.1371/journal.pone.0017433, PubMed 21390283

Publications 2010

  1. Gunnarsen KS, Lunde E, Kristiansen PE, Bogen B, Sandlie I, Løset GÅ (2010)
    Periplasmic expression of soluble single chain T cell receptors is rescued by the chaperone FkpA
    BMC Biotechnol, 10, 8
    DOI 10.1186/1472-6750-10-8, PubMed 20128915
  2. Heinzelmann K, Scholz BA, Nowak A, Fossum E, Kremmer E, Haas J, Frank R, Kempkes B (2010)
    Kaposi's sarcoma-associated herpesvirus viral interferon regulatory factor 4 (vIRF4/K10) is a novel interaction partner of CSL/CBF1, the major downstream effector of Notch signaling
    J Virol, 84 (23), 12255-64
    DOI 10.1128/JVI.01484-10, PubMed 20861242
  3. Jacobsen JT, Lunde E, Sundvold-Gjerstad V, Munthe LA, Bogen B (2010)
    The cellular mechanism by which complementary Id+ and anti-Id antibodies communicate: T cells integrated into idiotypic regulation
    Immunol Cell Biol, 88 (5), 515-22
    DOI 10.1038/icb.2009.118, PubMed 20066000
  4. Lunde E, Løset GÅ, Bogen B, Sandlie I (2010)
    Stabilizing mutations increase secretion of functional soluble TCR-Ig fusion proteins
    BMC Biotechnol, 10, 61
    DOI 10.1186/1472-6750-10-61, PubMed 20735812
  5. Ruffini PA, Grødeland G, Fredriksen AB, Bogen B (2010)
    Human chemokine MIP1α increases efficiency of targeted DNA fusion vaccines
    Vaccine, 29 (2), 191-9
    DOI 10.1016/j.vaccine.2010.10.057, PubMed 21055498

Publications 2009

  1. Bogen B, Ruffini P (2009)
    Review: to what extent are T cells tolerant to immunoglobulin variable regions?
    Scand J Immunol, 70 (6), 526-30
    DOI 10.1111/j.1365-3083.2009.02340.x, PubMed 19906193
  2. Corthay A, Lundin KU, Lorvik KB, Hofgaard PO, Bogen B (2009)
    Secretion of tumor-specific antigen by myeloma cells is required for cancer immunosurveillance by CD4+ T cells
    Cancer Res, 69 (14), 5901-7
    DOI 10.1158/0008-5472.CAN-08-4816, PubMed 19567679
  3. Fossum E, Friedel CC, Rajagopala SV, Titz B, Baiker A, Schmidt T, Kraus T, Stellberger T, Rutenberg C, Suthram S, Bandyopadhyay S, Rose D, von Brunn A, Uhlmann M, Zeretzke C, Dong YA, Boulet H, Koegl M, Bailer SM, Koszinowski U, Ideker T, Uetz P, Zimmer R, Haas J (2009)
    Evolutionarily conserved herpesviral protein interaction networks
    PLoS Pathog, 5 (9), e1000570
    DOI 10.1371/journal.ppat.1000570, PubMed 19730696
  4. Ghumra A, Shi J, Mcintosh RS, Rasmussen IB, Braathen R, Johansen FE, Sandlie I, Mongini PK, Areschoug T, Lindahl G, Lewis MJ, Woof JM, Pleass RJ (2009)
    Structural requirements for the interaction of human IgM and IgA with the human Fcalpha/mu receptor
    Eur J Immunol, 39 (4), 1147-56
    DOI 10.1002/eji.200839184, PubMed 19266484
  5. Holmøy T, Vartdal F, Hestvik AL, Munthe L, Bogen B (2009)
    The idiotype connection: linking infection and multiple sclerosis
    Trends Immunol, 31 (2), 56-62
    DOI 10.1016/j.it.2009.11.001, PubMed 19962346
  6. Huszthy PC, Giroglou T, Tsinkalovsky O, Euskirchen P, Skaftnesmo KO, Bjerkvig R, von Laer D, Miletic H (2009)
    Remission of invasive, cancer stem-like glioblastoma xenografts using lentiviral vector-mediated suicide gene therapy
    PLoS One, 4 (7), e6314
    DOI 10.1371/journal.pone.0006314, PubMed 19617915
  7. Huszthy PC, Immervoll H, Wang J, Goplen D, Miletic H, Eide GE, Bjerkvig R (2009)
    Cellular effects of oncolytic viral therapy on the glioblastoma microenvironment
    Gene Ther, 17 (2), 202-16
    DOI 10.1038/gt.2009.130, PubMed 19829315
  8. Wang J, Miletic H, Sakariassen PØ, Huszthy PC, Jacobsen H, Brekkå N, Li X, Zhao P, Mørk S, Chekenya M, Bjerkvig R, Enger PØ (2009)
    A reproducible brain tumour model established from human glioblastoma biopsies
    BMC Cancer, 9, 465
    DOI 10.1186/1471-2407-9-465, PubMed 20040089
  9. Zangani M, Carlsen H, Kielland A, Os A, Hauglin H, Blomhoff R, Munthe LA, Bogen B (2009)
    Tracking early autoimmune disease by bioluminescent imaging of NF-kappaB activation reveals pathology in multiple organ systems
    Am J Pathol, 174 (4), 1358-67
    DOI 10.2353/ajpath.2009.080700, PubMed 19286564

Publications 2008

  1. Flobakk M, Rasmussen IB, Lunde E, Frigstad T, Berntzen G, Michaelsen TE, Bogen B, Sandlie I (2008)
    Processing of an antigenic sequence from IgG constant domains for presentation by MHC class II
    J Immunol, 181 (10), 7062-72
    DOI 10.4049/jimmunol.181.10.7062, PubMed 18981126
  2. Ghumra A, Semblat JP, McIntosh RS, Raza A, Rasmussen IB, Braathen R, Johansen FE, Sandlie I, Mongini PK, Rowe JA, Pleass RJ (2008)
    Identification of residues in the Cmu4 domain of polymeric IgM essential for interaction with Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1)
    J Immunol, 181 (3), 1988-2000
    DOI 10.4049/jimmunol.181.3.1988, PubMed 18641336
  3. Huszthy PC, Goplen D, Thorsen F, Immervoll H, Wang J, Gutermann A, Miletic H, Bjerkvig R (2008)
    Oncolytic herpes simplex virus type-1 therapy in a highly infiltrative animal model of human glioblastoma
    Clin Cancer Res, 14 (5), 1571-80
    DOI 10.1158/1078-0432.CCR-07-2000, PubMed 18316582
  4. Tunheim G, Schjetne KW, Rasmussen IB, Sollid LM, Sandlie I, Bogen B (2008)
    Recombinant antibodies for delivery of antigen: a single loop between beta-strands in the constant region can accommodate long, complex and tandem T cell epitopes
    Int Immunol, 20 (3), 295-306
    DOI 10.1093/intimm/dxm141, PubMed 18252695
  5. Wu L, Fossum E, Joo CH, Inn KS, Shin YC, Johannsen E, Hutt-Fletcher LM, Hass J, Jung JU (2008)
    Epstein-Barr virus LF2: an antagonist to type I interferon
    J Virol, 83 (2), 1140-6
    DOI 10.1128/JVI.00602-08, PubMed 18987133

Publications 2007

  1. Braathen R, Hohman VS, Brandtzaeg P, Johansen FE (2007)
    Secretory antibody formation: conserved binding interactions between J chain and polymeric Ig receptor from humans and amphibians
    J Immunol, 178 (3), 1589-97
    DOI 10.4049/jimmunol.178.3.1589, PubMed 17237408
  2. Fredriksen AB, Bogen B (2007)
    Chemokine-idiotype fusion DNA vaccines are potentiated by bivalency and xenogeneic sequences
    Blood, 110 (6), 1797-805
    DOI 10.1182/blood-2006-06-032938, PubMed 17540847
  3. Frøyland M, Thompson KM, Thorpe SJ, Sahota SS, Gedde-Dahl T, Bogen B (2007)
    A VH4-34+ myeloma protein with weak autoreactivity
    Haematologica, 92 (5), 690-3
    DOI 10.3324/haematol.10850, PubMed 17488696
  4. Hestvik AL, Vartdal F, Fredriksen AB, Thompson KM, Kvale EO, Skorstad G, Bogen B, Holmoy T (2007)
    T cells from multiple sclerosis patients recognize multiple epitopes on Self-IgG
    Scand J Immunol, 66 (4), 393-401
    DOI 10.1111/j.1365-3083.2007.01955.x, PubMed 17850583
  5. Kolltveit KM, Granum S, Aasheim HC, Forsbring M, Sundvold-Gjerstad V, Dai KZ, Molberg O, Schjetne KW, Bogen B, Shapiro VS, Johansen FE, Schenck K, Spurkland A (2007)
    Expression of SH2D2A in T-cells is regulated both at the transcriptional and translational level
    Mol Immunol, 45 (8), 2380-90
    DOI 10.1016/j.molimm.2007.11.005, PubMed 18160104
  6. Løset GÅ, Lunde E, Bogen B, Brekke OH, Sandlie I (2007)
    Functional phage display of two murine alpha/beta T-cell receptors is strongly dependent on fusion format, mode and periplasmic folding assistance
    Protein Eng Des Sel, 20 (9), 461-72
    DOI 10.1093/protein/gzm044, PubMed 17925331
  7. Ráki M, Schjetne KW, Stamnaes J, Molberg Ø, Jahnsen FL, Issekutz TB, Bogen B, Sollid LM (2007)
    Surface expression of transglutaminase 2 by dendritic cells and its potential role for uptake and presentation of gluten peptides to T cells
    Scand J Immunol, 65 (3), 213-20
    DOI 10.1111/j.1365-3083.2006.01881.x, PubMed 17309775
  8. Schjetne KW, Fredriksen AB, Bogen B (2007)
    Delivery of antigen to CD40 induces protective immune responses against tumors
    J Immunol, 178 (7), 4169-76
    DOI 10.4049/jimmunol.178.7.4169, PubMed 17371973
  9. Tunheim G, Thompson KM, Fredriksen AB, Espevik T, Schjetne KW, Bogen B (2007)
    Human receptors of innate immunity (CD14, TLR2) are promising targets for novel recombinant immunoglobulin-based vaccine candidates
    Vaccine, 25 (24), 4723-34
    DOI 10.1016/j.vaccine.2007.04.004, PubMed 17499405
  10. Zangani MM, Frøyland M, Qiu GY, Meza-Zepeda LA, Kutok JL, Thompson KM, Munthe LA, Bogen B (2007)
    Lymphomas can develop from B cells chronically helped by idiotype-specific T cells
    J Exp Med, 204 (5), 1181-91
    DOI 10.1084/jem.20061220, PubMed 17485509

Publications 2006

  1. Bogen B, Ruffini PA, Corthay A, Fredriksen AB, Frøyland M, Lundin K, Røsjø E, Thompson K, Massaia M (2006)
    Idiotype-specific immunotherapy in multiple myeloma: suggestions for future directions of research
    Haematologica, 91 (7), 941-8
    PubMed 16818282
  2. Braathen R, Sandvik A, Berntzen G, Hammerschmidt S, Fleckenstein B, Sandlie I, Brandtzaeg P, Johansen FE, Lauvrak V (2006)
    Identification of a polymeric Ig receptor binding phage-displayed peptide that exploits epithelial transcytosis without dimeric IgA competition
    J Biol Chem, 281 (11), 7075-81
    DOI 10.1074/jbc.M508509200, PubMed 16423833
  3. Fredriksen AB, Sandlie I, Bogen B (2006)
    DNA vaccines increase immunogenicity of idiotypic tumor antigen by targeting novel fusion proteins to antigen-presenting cells
    Mol Ther, 13 (4), 776-85
    DOI 10.1016/j.ymthe.2005.10.019, PubMed 16414309
  4. Husebye H, Halaas Ø, Stenmark H, Tunheim G, Sandanger Ø, Bogen B, Brech A, Latz E, Espevik T (2006)
    Endocytic pathways regulate Toll-like receptor 4 signaling and link innate and adaptive immunity
    EMBO J, 25 (4), 683-92
    DOI 10.1038/sj.emboj.7600991, PubMed 16467847
  5. Huszthy PC, Brekken C, Pedersen TB, Thorsen F, Sakariassen PO, Skaftnesmo KO, Haraldseth O, Lønning PE, Bjerkvig R, Enger PO (2006)
    Antitumor efficacy improved by local delivery of species-specific endostatin
    J Neurosurg, 104 (1), 118-28
    DOI 10.3171/jns.2006.104.1.118, PubMed 16509155
  6. Kjeken R, Bogen B, Mathiesen I (2006)
    [DNA--the future in vaccine technology?]
    Tidsskr Nor Laegeforen, 126 (22), 2964-8
    PubMed 17117196
  7. Thorsen F, Afione S, Huszthy PC, Tysnes BB, Svendsen A, Bjerkvig R, Kotin RM, Lønning PE, Hoover F (2006)
    Adeno-associated virus (AAV) serotypes 2, 4 and 5 display similar transduction profiles and penetrate solid tumor tissue in models of human glioma
    J Gene Med, 8 (9), 1131-40
    DOI 10.1002/jgm.939, PubMed 16810631

Publications 2005

  1. Corthay A, Skovseth DK, Lundin KU, Røsjø E, Omholt H, Hofgaard PO, Haraldsen G, Bogen B (2005)
    Primary antitumor immune response mediated by CD4+ T cells
    Immunity, 22 (3), 371-83
    DOI 10.1016/j.immuni.2005.02.003, PubMed 15780993
  2. Holmøy T, Fredriksen AB, Thompson KM, Hestvik AL, Bogen B, Vartdal F (2005)
    Cerebrospinal fluid T cell clones from patients with multiple sclerosis: recognition of idiotopes on monoclonal IgG secreted by autologous cerebrospinal fluid B cells
    Eur J Immunol, 35 (6), 1786-94
    DOI 10.1002/eji.200425417, PubMed 15864781
  3. Huszthy PC, Svendsen A, Wilson JM, Kotin RM, Lønning PE, Bjerkvig R, Hoover F (2005)
    Widespread dispersion of adeno-associated virus serotype 1 and adeno-associated virus serotype 6 vectors in the rat central nervous system and in human glioblastoma multiforme xenografts
    Hum Gene Ther, 16 (3), 381-92
    DOI 10.1089/hum.2005.16.381, PubMed 15812233
  4. Munthe LA, Corthay A, Os A, Zangani M, Bogen B (2005)
    Systemic autoimmune disease caused by autoreactive B cells that receive chronic help from Ig V region-specific T cells
    J Immunol, 175 (4), 2391-400
    DOI 10.4049/jimmunol.175.4.2391, PubMed 16081810
  5. Schjetne KW, Thommesen JE, Fredriksen AB, Lunde E, Sandlie I, Bogen B (2005)
    Induction of central T cell tolerance: recombinant antibodies deliver peptides for deletion of antigen-specific (CD4+)8+ thymocytes
    Eur J Immunol, 35 (11), 3142-52
    DOI 10.1002/eji.200425947, PubMed 16184515
  6. Uetz P, Dong YA, Zeretzke C, Atzler C, Baiker A, Berger B, Rajagopala SV, Roupelieva M, Rose D, Fossum E, Haas J (2005)
    Herpesviral protein networks and their interaction with the human proteome
    Science, 311 (5758), 239-42
    DOI 10.1126/science.1116804, PubMed 16339411

Publications 2004

  1. Corthay A, Lundin KU, Munthe LA, Frøyland M, Gedde-Dahl T, Dembic Z, Bogen B (2004)
    Immunotherapy in multiple myeloma: Id-specific strategies suggested by studies in animal models
    Cancer Immunol Immunother, 53 (9), 759-69
    DOI 10.1007/s00262-004-0504-1, PubMed 15088126
  2. Dembic Z, Hofgaard PO, Omholt H, Bogen B (2004)
    Anti-class II antibodies, but not cytotoxic T-lymphocyte antigen 4-immunoglobulin hybrid molecules, prevent rejection of major histocompatibility complex class II-negative myeloma in T-cell receptor-transgenic mice
    Scand J Immunol, 60 (1-2), 143-52
    DOI 10.1111/j.0300-9475.2004.01435.x, PubMed 15238083
  3. Etokebe GE, Abrahamsen TG, Bogen B, Spurkland A (2004)
    Tumour necrosis factor receptor superfamily member 6 gene mutation detection by denaturing high-performance liquid chromatography
    Scand J Immunol, 59 (5), 496-503
    DOI 10.1111/j.0300-9475.2004.01422.x, PubMed 15140060
  4. Lundin KU, Screpanti V, Omholt H, Hofgaard PO, Yagita H, Grandien A, Bogen B (2004)
    CD4+ T cells kill Id+ B-lymphoma cells: FasLigand-Fas interaction is dominant in vitro but is redundant in vivo
    Cancer Immunol Immunother, 53 (12), 1135-45
    DOI 10.1007/s00262-004-0538-4, PubMed 15696611
  5. Munthe LA, Os A, Zangani M, Bogen B (2004)
    MHC-restricted Ig V region-driven T-B lymphocyte collaboration: B cell receptor ligation facilitates switch to IgG production
    J Immunol, 172 (12), 7476-84
    DOI 10.4049/jimmunol.172.12.7476, PubMed 15187126
  6. Ruffini PA, Biragyn A, Coscia M, Harvey LK, Cha SC, Bogen B, Kwak LW (2004)
    Genetic fusions with viral chemokines target delivery of nonimmunogenic antigen to trigger antitumor immunity independent of chemotaxis
    J Leukoc Biol, 76 (1), 77-85
    DOI 10.1189/jlb.1003481, PubMed 15075363
  7. Tjelle TE, Corthay A, Lunde E, Sandlie I, Michaelsen TE, Mathiesen I, Bogen B (2004)
    Monoclonal antibodies produced by muscle after plasmid injection and electroporation
    Mol Ther, 9 (3), 328-36
    DOI 10.1016/j.ymthe.2003.12.007, PubMed 15006599
  8. Tunheim G, Schjetne KW, Fredriksen AB, Sandlie I, Bogen B (2004)
    Human CD14 is an efficient target for recombinant immunoglobulin vaccine constructs that deliver T cell epitopes
    J Leukoc Biol, 77 (3), 303-10
    DOI 10.1189/jlb.0804480, PubMed 15576418

Publications 2003

  1. Dellacasagrande J, Schreurs OJ, Hofgaard PO, Omholt H, Steinsvoll S, Schenck K, Bogen B, Dembic Z (2003)
    Liver metastasis of cancer facilitated by chemokine receptor CCR6
    Scand J Immunol, 57 (6), 534-44
    DOI 10.1046/j.1365-3083.2003.01263.x, PubMed 12791091
  2. Elm C, Braathen R, Bergmann S, Frank R, Vaerman JP, Kaetzel CS, Chhatwal GS, Johansen FE, Hammerschmidt S (2003)
    Ectodomains 3 and 4 of human polymeric Immunoglobulin receptor (hpIgR) mediate invasion of Streptococcus pneumoniae into the epithelium
    J Biol Chem, 279 (8), 6296-304
    DOI 10.1074/jbc.M310528200, PubMed 14660617
  3. Lundin KU, Hofgaard PO, Omholt H, Munthe LA, Corthay A, Bogen B (2003)
    Therapeutic effect of idiotype-specific CD4+ T cells against B-cell lymphoma in the absence of anti-idiotypic antibodies
    Blood, 102 (2), 605-12
    DOI 10.1182/blood-2002-11-3381, PubMed 12649166
  4. Schjetne KW, Gundersen HT, Iversen JG, Thompson KM, Bogen B (2003)
    Antibody-mediated delivery of antigen to chemokine receptors on antigen-presenting cells results in enhanced CD4+ T cell responses
    Eur J Immunol, 33 (11), 3101-8
    DOI 10.1002/eji.200324299, PubMed 14579278
  5. Schjetne KW, Thompson KM, Nilsen N, Flo TH, Fleckenstein B, Iversen JG, Espevik T, Bogen B (2003)
    Cutting edge: link between innate and adaptive immunity: Toll-like receptor 2 internalizes antigen for presentation to CD4+ T cells and could be an efficient vaccine target
    J Immunol, 171 (1), 32-6
    DOI 10.4049/jimmunol.171.1.32, PubMed 12816980
  6. Thorsen F, Ersland L, Nordli H, Enger PO, Huszthy PC, Lundervold A, Standnes T, Bjerkvig R, Lund-Johansen M (2003)
    Imaging of experimental rat gliomas using a clinical MR scanner
    J Neurooncol, 63 (3), 225-31
    DOI 10.1023/a:1024241905888, PubMed 12892228

Publications 2002

  1. Bogen B (2002)
    A mouse model for immunotherapy of myeloma
    Hematol J, 3 (5), 224-9
    DOI 10.1038/sj.thj.6200183, PubMed 12391539
  2. Braathen R, Sorensen V, Brandtzaeg P, Sandlie I, Johansen FE (2002)
    The carboxyl-terminal domains of IgA and IgM direct isotype-specific polymerization and interaction with the polymeric immunoglobulin receptor
    J Biol Chem, 277 (45), 42755-62
    DOI 10.1074/jbc.M205502200, PubMed 12213814
  3. Lunde E, Lauvrak V, Rasmussen IB, Schjetne KW, Thompson KM, Michaelsen TE, Brekke OH, Sollid LM, Bogen B, Sandlie I (2002)
    Troybodies and pepbodies
    Biochem Soc Trans, 30 (4), 500-6
    DOI 10.1042/bst0300500, PubMed 12196123
  4. Lunde E, Western KH, Rasmussen IB, Sandlie I, Bogen B (2002)
    Efficient delivery of T cell epitopes to APC by use of MHC class II-specific Troybodies
    J Immunol, 168 (5), 2154-62
    DOI 10.4049/jimmunol.168.5.2154, PubMed 11859101
  5. Schjetne KW, Thompson KM, Aarvak T, Fleckenstein B, Sollid LM, Bogen B (2002)
    A mouse C kappa-specific T cell clone indicates that DC-SIGN is an efficient target for antibody-mediated delivery of T cell epitopes for MHC class II presentation
    Int Immunol, 14 (12), 1423-30
    DOI 10.1093/intimm/dxf110, PubMed 12456590

Publications 2001

  1. Dembic Z, Røttingen JA, Dellacasagrande J, Schenck K, Bogen B (2001)
    Phagocytic dendritic cells from myelomas activate tumor-specific T cells at a single cell level
    Blood, 97 (9), 2808-14
    DOI 10.1182/blood.v97.9.2808, PubMed 11313275
  2. Johansen FE, Braathen R, Brandtzaeg P (2001)
    The J chain is essential for polymeric Ig receptor-mediated epithelial transport of IgA
    J Immunol, 167 (9), 5185-92
    DOI 10.4049/jimmunol.167.9.5185, PubMed 11673531
  3. Lund E, Rasmussen IB, Western KH, Eidem JK, Sandlie I, Bogen B (2001)
    "Troy-bodies": recombinant antibodies that target T cell epitopes to antigen presenting cells
    Int Rev Immunol, 20 (5), 647-73
    DOI 10.3109/08830180109045583, PubMed 11890617
  4. Lunde E, Rasmussen IB, Eidem JK, Gregers TF, Western KH, Bogen B, Sandlie I (2001)
    'Troy-bodies': antibodies as vector proteins for T cell epitopes
    Biomol Eng, 18 (3), 109-16
    DOI 10.1016/s1389-0344(01)00091-0, PubMed 11566602
  5. McAdam SN, Fleckenstein B, Rasmussen IB, Schmid DG, Sandlie I, Bogen B, Viner NJ, Sollid LM (2001)
    T cell recognition of the dominant I-A(k)-restricted hen egg lysozyme epitope: critical role for asparagine deamidation
    J Exp Med, 193 (11), 1239-46
    DOI 10.1084/jem.193.11.1239, PubMed 11390431
  6. Rasmussen IB, Lunde E, Michaelsen TE, Bogen B, Sandlie I (2001)
    The principle of delivery of T cell epitopes to antigen-presenting cells applied to peptides from influenza virus, ovalbumin, and hen egg lysozyme: implications for peptide vaccination
    Proc Natl Acad Sci U S A, 98 (18), 10296-301
    DOI 10.1073/pnas.181336898, PubMed 11517321
  7. Read TA, Farhadi M, Bjerkvig R, Olsen BR, Rokstad AM, Huszthy PC, Vajkoczy P (2001)
    Intravital microscopy reveals novel antivascular and antitumor effects of endostatin delivered locally by alginate-encapsulated cells
    Cancer Res, 61 (18), 6830-7
    PubMed 11559558

Publications 2000

  1. Bogen B, Schenck K, Munthe LA, Dembic Z (2000)
    Deletion of idiotype (Id)-specific T cells in multiple myeloma
    Acta Oncol, 39 (7), 783-8
    DOI 10.1080/028418600750063505, PubMed 11145433
  2. Dembic Z, Schenck K, Bogen B (2000)
    Dendritic cells purified from myeloma are primed with tumor-specific antigen (idiotype) and activate CD4+ T cells
    Proc Natl Acad Sci U S A, 97 (6), 2697-702
    DOI 10.1073/pnas.050579897, PubMed 10706628
  3. Eidem JK, Rasmussen IB, Lunde E, Gregers TF, Rees AR, Bogen B, Sandlie I (2000)
    Recombinant antibodies as carrier proteins for sub-unit vaccines: influence of mode of fusion on protein production and T-cell activation
    J Immunol Methods, 245 (1-2), 119-31
    DOI 10.1016/s0022-1759(00)00274-x, PubMed 11042289
  4. Johansen FE, Braathen R, Brandtzaeg P (2000)
    Role of J chain in secretory immunoglobulin formation
    Scand J Immunol, 52 (3), 240-8
    DOI 10.1046/j.1365-3083.2000.00790.x, PubMed 10972899

Publications 1999

  1. Djerbi M, Screpanti V, Catrina AI, Bogen B, Biberfeld P, Grandien A (1999)
    The inhibitor of death receptor signaling, FLICE-inhibitory protein defines a new class of tumor progression factors
    J Exp Med, 190 (7), 1025-32
    DOI 10.1084/jem.190.7.1025, PubMed 10510092
  2. Lunde E, Munthe LA, Vabø A, Sandlie I, Bogen B (1999)
    Antibodies engineered with IgD specificity efficiently deliver integrated T-cell epitopes for antigen presentation by B cells
    Nat Biotechnol, 17 (7), 670-5
    DOI 10.1038/10883, PubMed 10404160
  3. Munthe LA, Kyte JA, Bogen B (1999)
    Resting small B cells present endogenous immunoglobulin variable-region determinants to idiotope-specific CD4(+) T cells in vivo
    Eur J Immunol, 29 (12), 4043-52
    DOI 10.1002/(SICI)1521-4141(199912)29:12<4043::AID-IMMU4043>3.0.CO;2-E, PubMed 10602015

Publications 1998

  1. Bogen B (1998)
    [Kaspase or caspase?]
    Tidsskr Nor Laegeforen, 118 (30), 4790
    PubMed 9914770
  2. Dembic Z, Munthe LA, Schenck K, Mueller C, Bogen B (1998)
    Transient overexpression of CD4 enhances allelic exclusion of T-cell receptor (TCR) alpha chains and promotes positive selection of class II-restricted TCR-transgenic thymocytes
    Mol Immunol, 35 (1), 23-38
    DOI 10.1016/s0161-5890(98)00004-2, PubMed 9683261
  3. Engel H, Bogen B, Müller U, Andersson J, Rolink A, Weiss S (1998)
    Expression level of a transgenic lambda2 chain results in isotype exclusion and commitment to B1 cells
    Eur J Immunol, 28 (8), 2289-99
    DOI 10.1002/(SICI)1521-4141(199808)28:08<2289::AID-IMMU2289>3.0.CO;2-Y, PubMed 9710207
  4. Lauritzsen GF, Hofgaard PO, Schenck K, Bogen B (1998)
    Clonal deletion of thymocytes as a tumor escape mechanism
    Int J Cancer, 78 (2), 216-22
    DOI 10.1002/(sici)1097-0215(19981005)78:2<216::aid-ijc16>3.0.co;2-8, PubMed 9754655
  5. Sim BC, Aftahi N, Reilly C, Bogen B, Schwartz RH, Gascoigne NR, Lo D (1998)
    Thymic skewing of the CD4/CD8 ratio maps with the T-cell receptor alpha-chain locus
    Curr Biol, 8 (12), 701-4
    DOI 10.1016/s0960-9822(98)70276-3, PubMed 9637921

Publications 1997

  1. Bogen B (1997)
    [University medicine in Silicon Valley]
    Tidsskr Nor Laegeforen, 117 (11), 1641-2
    PubMed 9198951
  2. Lunde E, Bogen B, Sandlie I (1997)
    Immunoglobulin as a vehicle for foreign antigenic peptides immunogenic to T cells
    Mol Immunol, 34 (16-17), 1167-76
    DOI 10.1016/s0161-5890(97)00143-0, PubMed 9566764
  3. Reichardt VL, Okada CY, Stockerl-Goldstein KE, Bogen B, Levy R (1997)
    Rationale for adjuvant idiotypic vaccination after high-dose therapy for multiple myeloma
    Biol Blood Marrow Transplant, 3 (3), 157-63
    PubMed 9310193

Publications 1996

  1. Blichfeldt E, Munthe LA, Røtnes JS, Bogen B (1996)
    Dual T cell receptor T cells have a decreased sensitivity to physiological ligands due to reduced density of each T cell receptor
    Eur J Immunol, 26 (12), 2876-84
    DOI 10.1002/eji.1830261211, PubMed 8977280
  2. Bogen B (1996)
    Peripheral T cell tolerance as a tumor escape mechanism: deletion of CD4+ T cells specific for a monoclonal immunoglobulin idiotype secreted by a plasmacytoma
    Eur J Immunol, 26 (11), 2671-9
    DOI 10.1002/eji.1830261119, PubMed 8921954
  3. Bot A, Nangpal A, Pricop L, Bogen B, Kaushik A, Bona CA (1996)
    V lambda-light chain genes reconstitute immune responses to defined carbohydrate antigens or haptens by utilizing different VH genes
    Mol Immunol, 33 (17-18), 1359-68
    DOI 10.1016/s0161-5890(96)00095-8, PubMed 9171895
  4. Munthe LA, Blichfeldt E, Sollien A, Dembic Z, Bogen B (1996)
    T cells with two Tcrbeta chains and reactivity to both MHC/idiotypic peptide and superantigen
    Cell Immunol, 170 (2), 283-90
    DOI 10.1006/cimm.1996.0162, PubMed 8660828

Publications 1995

  1. Bogen B, Munthe L, Sollien A, Hofgaard P, Omholt H, Dagnaes F, Dembic Z, Lauritzsen GF (1995)
    Naive CD4+ T cells confer idiotype-specific tumor resistance in the absence of antibodies
    Eur J Immunol, 25 (11), 3079-86
    DOI 10.1002/eji.1830251114, PubMed 7489746
  2. Dybwad A, Bogen B, Natvig JB, Førre O, Sioud M (1995)
    Peptide phage libraries can be an efficient tool for identifying antibody ligands for polyclonal antisera
    Clin Exp Immunol, 102 (2), 438-42
    DOI 10.1111/j.1365-2249.1995.tb03802.x, PubMed 7586703
  3. Munthe LA, Sollien A, Dembic Z, Bogen B (1995)
    Preferential positive selection of T lymphocytes which express two different TCR alpha chains, an endogenous and a transgenic
    Scand J Immunol, 42 (6), 651-61
    DOI 10.1111/j.1365-3083.1995.tb03708.x, PubMed 8552989

Publications 1994

  1. Dembić Z, Weiss S, Bogen B (1994)
    Thymic selection of immunoglobulin idiotype specific T-cells
    Thymus, 22 (3), 141-52
    PubMed 7940642
  2. Lauritzsen GF, Weiss S, Dembic Z, Bogen B (1994)
    Naive idiotype-specific CD4+ T cells and immunosurveillance of B-cell tumors
    Proc Natl Acad Sci U S A, 91 (12), 5700-4
    DOI 10.1073/pnas.91.12.5700, PubMed 7911244
  3. Røtnes JS, Bogen B (1994)
    Ca2+ mobilization in physiologically stimulated single T cells gradually increases with peptide concentration (analog signaling)
    Eur J Immunol, 24 (4), 851-8
    DOI 10.1002/eji.1830240412, PubMed 8149956

Publications 1993

  1. Bogen B, Dembic Z, Weiss S (1993)
    Clonal deletion of specific thymocytes by an immunoglobulin idiotype
    EMBO J, 12 (1), 357-63
    DOI 10.1002/j.1460-2075.1993.tb05664.x, PubMed 8428591
  2. Bogen B, Gleditsch L, Teig A (1993)
    T-cell receptor alpha haplotype influences V alpha epitope expression on both cortisone-resistant thymocytes and lymph node T cells
    Scand J Immunol, 37 (6), 690-5
    DOI 10.1111/j.1365-3083.1993.tb01685.x, PubMed 7686302
  3. Bogen B, Weiss S (1993)
    Processing and presentation of idiotypes to MHC-restricted T cells
    Int Rev Immunol, 10 (4), 337-55
    DOI 10.3109/08830189309061709, PubMed 8294847
  4. Lauritzsen GF, Bogen B (1993)
    The role of idiotype-specific, CD4+ T cells in tumor resistance against major histocompatibility complex class II molecule negative plasmacytoma cells
    Cell Immunol, 148 (1), 177-88
    DOI 10.1006/cimm.1993.1100, PubMed 8098665
  5. Lauritzsen GF, Weiss S, Bogen B (1993)
    Anti-tumour activity of idiotype-specific, MHC-restricted Th1 and Th2 clones in vitro and in vivo
    Scand J Immunol, 37 (1), 77-85
    DOI 10.1111/j.1365-3083.1993.tb01668.x, PubMed 8418475

Publications 1992

  1. Bogen B, Gleditsch L, Weiss S, Dembic Z (1992)
    Weak positive selection of transgenic T cell receptor-bearing thymocytes: importance of major histocompatibility complex class II, T cell receptor and CD4 surface molecule densities
    Eur J Immunol, 22 (3), 703-9
    DOI 10.1002/eji.1830220313, PubMed 1547816
  2. Gleditsch L, Bogen B (1992)
    A Tcra congenic mouse: V alpha epitope expression is influenced by both Tcra haplotypes and background genes
    Immunogenetics, 35 (3), 153-60
    DOI 10.1007/BF00185108, PubMed 1371498
  3. Snodgrass HR, Fisher AM, Bruyns E, Bogen B (1992)
    Restricted alpha/beta receptor gene usage of idiotype-specific major histocompatibility complex-restricted T cells: selection for CDR3-related sequences
    Eur J Immunol, 22 (8), 2169-72
    DOI 10.1002/eji.1830220832, PubMed 1379189

Publications 1991

  1. Bogen B, Weiss S (1991)
    A rearranged lambda 2 light gene chain retards but does not exclude kappa and lambda 1 expression
    Eur J Immunol, 21 (10), 2391-5
    DOI 10.1002/eji.1830211015, PubMed 1915552
  2. Lauritzsen GF, Bogen B (1991)
    Idiotype-specific, major histocompatibility complex restricted T cells are of both Th1 and Th2 type
    Scand J Immunol, 33 (6), 647-56
    DOI 10.1111/j.1365-3083.1991.tb02537.x, PubMed 1675480
  3. Weiss S, Bogen B (1991)
    MHC class II-restricted presentation of intracellular antigen
    Cell, 64 (4), 767-76
    DOI 10.1016/0092-8674(91)90506-t, PubMed 1847667

Publications 1990

  1. Bogen B, Lauritzsen GF, Weiss S (1990)
    A stimulatory monoclonal antibody detecting T cell receptor diversity among idiotype-specific, major histocompatibility complex-restricted T cell clones
    Eur J Immunol, 20 (10), 2359-62
    DOI 10.1002/eji.1830201030, PubMed 1700755
  2. Gleditsch L, Snodgrass R, Bogen B (1990)
    No recombinations between Tcra-V and Tcra-C gene segments in 669 backcross mice
    Immunogenetics, 32 (5), 297-303
    DOI 10.1007/BF00211642, PubMed 1979062

Publications 1989

  1. Bogen B (1989)
    Monoclonal antibodies specific for variable and constant domains of murine lambda chains
    Scand J Immunol, 29 (3), 273-9
    DOI 10.1111/j.1365-3083.1989.tb01125.x, PubMed 2497510
  2. Bogen B, Lambris JD (1989)
    Minimum length of an idiotypic peptide and a model for its binding to a major histocompatibility complex class II molecule
    EMBO J, 8 (7), 1947-52
    DOI 10.1002/j.1460-2075.1989.tb03599.x, PubMed 2792076
  3. Weiss S, Bogen B (1989)
    B-lymphoma cells process and present their endogenous immunoglobulin to major histocompatibility complex-restricted T cells
    Proc Natl Acad Sci U S A, 86 (1), 282-6
    DOI 10.1073/pnas.86.1.282, PubMed 2492101

Publications 1988

  1. Bogen B, Weiss S (1988)
    B lymphoma cells process and present their endogenous IG: implications for network theory
    Adv Exp Med Biol, 237, 877-82
    DOI 10.1007/978-1-4684-5535-9_131, PubMed 3267071

Publications 1986

  1. Bogen B, Malissen B, Haas W (1986)
    Idiotope-specific T cell clones that recognize syngeneic immunoglobulin fragments in the context of class II molecules
    Eur J Immunol, 16 (11), 1373-8
    DOI 10.1002/eji.1830161110, PubMed 3096740
  2. Bogen B, Snodgrass R, Briand JP, Hannestad K (1986)
    Synthetic peptides and beta-chain gene rearrangements reveal a diversified T cell repertoire for a lambda light chain third hypervariable region
    Eur J Immunol, 16 (11), 1379-84
    DOI 10.1002/eji.1830161111, PubMed 3096741

Publications 1985

  1. Bogen B (1985)
    Dominant suppressive effect of the silent Eb alpha allele on an in vivo T helper cell response under Ed beta Ed alpha region-linked immune response gene control
    Eur J Immunol, 15 (10), 1033-7
    DOI 10.1002/eji.1830151014, PubMed 2932337
  2. Bogen B, Jørgensen T, Hannestad K (1985)
    T helper cell recognition of idiotopes on lambda 2 light chains of M315 and T952: evidence for dependence on somatic mutations in the third hypervariable region
    Eur J Immunol, 15 (3), 278-81
    DOI 10.1002/eji.1830150313, PubMed 2579823
  3. Jørgensen T, Bogen B, Hannestad K (1985)
    H-2-linked Ir genes have a striking influence on the immunogenicity of idiotopes of myeloma protein 315 for T helper cells
    Scand J Immunol, 21 (2), 183-7
    DOI 10.1111/j.1365-3083.1985.tb01418.x, PubMed 3156401

Publications 1984

  1. Bogen B (1984)
    Antibody responses to lambda 1J558 and lambda 2315 light chains. Specificity and genetic regulation
    Scand J Immunol, 20 (5), 413-24
    DOI 10.1111/j.1365-3083.1984.tb01020.x, PubMed 6209791
  2. Bogen B (1984)
    H-2 and non-H-2 genes complement each other for a carrier (idiotype)-specific Th response
    Immunogenetics, 20 (4), 453-7
    DOI 10.1007/BF00345619, PubMed 6237990
  3. Bogen B, Hannestad K (1984)
    Determinant-specific regulation of T helper cell responses to murine lambda light chains by both H-2 and non-H-2 genes
    Eur J Immunol, 14 (2), 158-63
    DOI 10.1002/eji.1830140210, PubMed 6199213
  4. Bogen B, Hannestad K (1984)
    Specificity of antibody and helper T-cell responses to the isologous myeloma protein W3129 and its subunits
    Mol Immunol, 21 (7), 653-61
    DOI 10.1016/0161-5890(84)90051-8, PubMed 6205254

Publications 1983

  1. Bogen B, Jørgensen T, Hannestad K (1983)
    Recognition of lambda 1 and lambda 2 murine light chains by carrier-specific isologous T helper cells; effect of L-H chain assembly
    Eur J Immunol, 13 (5), 353-9
    DOI 10.1002/eji.1830130502, PubMed 6189725
  2. Jørgensen T, Bogen B, Hannestad K (1983)
    T helper cells recognize an idiotope located on peptide 88-114/117 of the light chain variable domain of an isologous myeloma protein (315)
    J Exp Med, 158 (6), 2183-8
    DOI 10.1084/jem.158.6.2183, PubMed 6227679

Publications 1982

  1. Marhaug G, Gaudernack G, Bogen B, Husby G (1982)
    Monoclonal hybridoma antibodies to human amyloid related protein SAA
    Clin Exp Immunol, 50 (2), 390-6
    PubMed 7151332

Publications 1981

  1. Myhre ES, Waldum HL, Burhol PG, Bogen B, Bostad L, Wesenberg F (1981)
    [Acquired idiopathic hypogammaglobulinemia. A patient protocol]
    Tidsskr Nor Laegeforen, 101 (7), 459-61
    PubMed 7209936